Table 4.
Multivariate analysis of variables for the prediction of survival outcomes in training cohort when interrelated SIRI and PLR are combined.
| Variables | Overall survival | Cancer-specific survival | Metastasis-free survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95%CI | P value | HR | 95%CI | P value | HR | 95%CI | P value | |
| Age (>65 vs. ≤ 65 years) | 2.202 | 1.274–3.792 | 0.004* | 1.696 | 0.919–3.129 | 0.091 | 1.563 | 0.955–2.559 | 0.076 |
| BMI (≥25 vs. <25) | 0.856 | 0.396–1.853 | 0.694 | 1.012 | 0.416–2.459 | 0.980 | 0.670 | 0.333–1.345 | 0.260 |
| ASA grade (≥3 vs. <3) | 1.425 | 0.822–2.471 | 0.207 | – | |||||
| Hydronephrosis (Yes vs. No) | 2.048 | 1.234–3.399 | 0.006* | 1.952 | 0.969–3.932 | 0.061 | 1.936 | 1.110–3.374 | 0.020* |
| SIRI-PLR | |||||||||
| Low SIRI + low PLR | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 |
| High SIRI + low PLR vs. low SIRI + low PLR | 1.087 | 0.473–2.499 | 0.844 | 1.388 | 0.546–3.530 | 0.491 | 0.806 | 0.369–1.760 | 0.588 |
| Low SIRI + high PLR vs. low SIRI + low PLR | 1.134 | 0.514–2.500 | 0.756 | 1.201 | 0.492–2.932 | 0.688 | 0.605 | 0.289–1.269 | 0.184 |
| High SIRI + high PLR vs. low SIRI + low PLR | 2.405 | 1.288–4.490 | 0.006* | 2.351 | 1.141–4.844 | 0.021* | 2.352 | 1.283–4.333 | 0.027* |
| Anemia (Yes vs. No) | 0.902 | 0.548–1.484 | 0.685 | 0.809 | 0.455–1.441 | 0.472 | 1.230 | 0.772–1.958 | 0.384 |
| Hypoproteinemia (Yes vs. No) | 0.843 | 0.410–1.733 | 0.642 | 0.906 | 0.401–2.048 | 0.812 | 0.771 | 0.370–1.608 | 0.488 |
| CKD stage | |||||||||
| CKD 1 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 |
| CKD 2–3 | 1.370 | 0.468–4.011 | 0.566 | 1.376 | 0.393–4.818 | 0.618 | 1.049 | 0.397–2.770 | 0.923 |
| CKD 4–5 | 1.267 | 0.370–4.336 | 0.706 | 1.358 | 0.324–5.694 | 0.675 | 1.279 | 0.401–4.075 | 0.678 |
| Tumor size (≥3 vs. <3) | 1.784 | 1.126–2.828 | 0.014* | 2.009 | 1.179–3.422 | 0.010* | 1.539 | 1.000–2.369 | 0.050 |
| Tumor site | |||||||||
| Pelvicalyceal | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 | |||
| Ureter | 1.917 | 1.031–3.566 | 0.040* | 1.574 | 0.937–2.643 | 0.086 | |||
| Both | 1.968 | 0.661–5.860 | 0.224 | 1.642 | 0.686–3.930 | 0.265 | |||
| Multifocality (Yes vs. No) | 1.015 | 0.583–1.769 | 0.957 | 1.174 | 0.637–2.163 | 0.607 | |||
| Pathologic T stage | |||||||||
| pT1 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 | 1.000 | Reference | 1.000 |
| pT2 vs. pT1 | 1.210 | 0.597–2.450 | 0.597 | 1.694 | 0.661–4.342 | 0.273 | 1.568 | 0.826–2.980 | 0.169 |
| pT3 vs. pT1 | 2.708 | 1.347–5.446 | 0.005* | 4.184 | 1.664–10.523 | 0.002* | 2.164 | 1.081–4.333 | 0.029* |
| pT4 vs. pT1 | 5.836 | 1.389–24.515 | 0.016* | 15.633 | 3.200–76.369 | 0.001* | 6.152 | 1.521–24.872 | 0.011* |
| N stage (N1 vs. N0) | 1.306 | 0.265–6.445 | 0.043* | 1.552 | 1.110–3.783 | 0.034* | 1.040 | 0.211–5.114 | 0.042* |
| Tumor grade (≥3 vs. <3) | 1.366 | 0.624–2.991 | 0.436 | 2.289 | 0.771–6.796 | 0.136 | 1.351 | 0.699–2.610 | 0.371 |
| LVI (Yes vs. No) | 1.627 | 0.741–3.574 | 0.225 | 2.568 | 1.106–5.967 | 0.028* | 1.251 | 0.563–2.781 | 0.582 |
| Adjuvant therapy (Yes vs. No) | 1.993 | 1.160–3.424 | 0.013* | 2.288 | 1.282–4.086 | 0.005* | 2.564 | 1.504–4.370 | 0.001* |
*
Statistically significant.